RecipientAmount (USD million)Deal/Technology HighlightCollaborator / InvestorDeal TypeCountry
MorphoSys AG, Galapagos NV1,095This is an exclusive global license agreement with Novartis, for MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications. Novartis will bear all future research, development, manufacturing and commercialization costs related to MOR106 and will be exclusively holding all rights for commercialization of the products.Novartis Pharma AG Licensing Agreement Germany
Anima Biotech1,050The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.Eli Lilly and CompanyCollaborationUnited States
PureTech Health1,000PureTech’s milk exosome-based technology is designed to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules. The exosome platform aims to package up drugs with large or complex payloads in a way that allows them to move through the digestive system without degrading so they can reach the target cell or tissue. Through the Collaboration, PureTech Health will receive up to $36 million upfront and will be eligible to potentially receive develoF. Hoffmann-La Roche AGCollaborationUnited States
Agilis Biotherapeutics, Inc.945The lead gene therapy candidate, GT-AADC, has compelling clinical data in treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. AADC Deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene.PTC TherapeuticsAcquisitionUnited States
Protalix BioTherapeutics, Inc.760Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the U.S. rights. The focus of the Partnership is on the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease.Chiesi Farmaceutici S.p.A.Supply Agreement Israel
Chugai Pharmabody Research Pte. Ltd.555CPR was established in 2012 to conduct research focused on the discovery of novel antibody drugs by utilizing innovative antibody engineering technologies owned by Chugai.Chugai Pharmaceutical ExpansionSingapore
Revolution Medicines500In the collaboration, the companies will jointly develop SHP2 inhibitors, which are designed to reduce cell growth signaling that is overactive in cancer. Both parties will contribute to the research and development program, with REVOLUTION Medicines continuing to lead research and early clinical development, and Sanofi leading later development activities for the program.SanofiPartnershipUnited States
Innovent Biologics500The IPO prospectus has not specified the size and pricing of the offering yet but an earlier report by Reuters said the Suzhou, Jiangsu province-based company is seeking to raise up to $500 million. Innovent has raised almost $600 million through five rounds of equity funding since its inception seven years ago. In April, Temasek joined a $150-million Series E funding round in the company.UndisclosedIPOChina
Modular Aseptic Processing (MAP) Unit465Known as Modular Aseptic Processing (MAP), the new, multi-story, 400,000-square-foot production facility will also support the area economy by creating an estimated 450 new jobs over the next several years. This expands Pfizer’s presence in Portage, located in Kalamazoo County, where the company now employs more than 2,200 people at one of its largest plants.Pfizer Inc. Manufacturing InvestmentUnited States
Swedish Orphan Biovitrum AB (publ) (Sobi™)450Strategic partnership to develop and commercialise emapalumab, a highly attractive late stage orphan drug candidate that addresses a high unmet medical need in primary Haemophagocytic lymphohistiocytosisNovimmune SALicensing Agreement Sweden
Visterra Inc.430Visterra’s Hierotope platform comprises novel computational and experimental technologies, which enables the design and engineering of precision antibody-based therapies that specifically bind to disease targets. Visterra’s pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases. Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, with an emphasis on proprietary drug discovery and develoOtsuka HoldingsAcquisitionUnited States
Halo Pharma425With the acquisition of Halo, Cambrex will enter the large and growing finished dosage form CDMO market. Halo provides drug product development and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. Halo’s core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances.Cambrex CorporationAcquisitionUnited States
Ascletis Pharma Inc400Ascletis, which makes anti-viral, cancer and liver disease drugs, sold 224 million new shares, or 20 percent of its enlarged share capital, at HK$14 ($1.78) each, the middle of a price range of HK$12 to HK$16, the people said. The deal values the company at $2 billion. Ascletis's lead products are Ganovo ® and ravidasvir, which are novel anti-viral drugs. Singapore sovereign wealth fund GIC Pte Ltd [GIC.UL] last week committed to buy $75 million worth of shares as a cornerstone investor.GIC Private LimitedIPOChina
GlaxoSmithKline330Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), has been tested as a topical treatment in more than 800 patients in phase 1 and 2. In a dose-ranging study involving 227 adults with plaque psoriasis, tapinarof brought about "clinically meaningful, dose-dependent improvements."Dermavant SciencesAsset AcquisitionUnited Kingdom
Bayer323Bayer’s global medical dermatology portfolio, which includes prescription treatment solutions for acne (Skinoren®), fungal skin infections (Travogen® and Travocort®) and rosacea (Finacea®), and a range of topical steroids (Advantan®, Nerisona®, and Desonate®). The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids.Leo PharmaBusiness Unit AcquisitionUnited States
Forbion IV Fund312Forbion IV, like its predecessor fund, Forbion III, will primarily focus on EU and the UK (together c. 80% of investment), with the remainder of the fund targeting opportunities in North America, and will have an even sharper focus on biotech.ForbionFinancingThe Netherlands
23andMe300The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialisation expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries.GlaxoSmithKlineCollaborationUnited States
Rubius Therapeutics274Rubius Therapeutics is pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs. Rubius has designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies.J.P. MorganIPOUnited States
Long Hill Capital Fund 2265Long Hill Capital has rapidly emerged to become a leader in healthcare and consumer investing in China, bringing total capital under management to over $400 million. New Enterprise AssociatesFinancingChina
Reata Pharmaceuticals, Inc.249Reata intends to use the net proceeds from the offering for working capital to advancing the development of bardoxolone methyl and omaveloxolone through clinical trials, preparing to file one or more New Drug Applications, and planning for commercialization of its potential products.Jefferies LLCIPOUnited States
Center for Veterinary Public Health231The company will establish the new site in the French Rhône-Alpes region, which is known as the European “vaccine valley”. With this investment, Boehringer Ingelheim’s Animal Health division will be able to respond to the growing global demand for foot-and-mouth disease and Bluetongue virus control. Boehringer IngelheimManufacturing InvestmentFrance
Gossamer Bio230Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in the autoimmune, allergy/inflammation, and immuno-oncology disease areas. The Company intends to use the proceeds from this financing for progress in the clinical trials for multiple early and late-stage drug candidates, and to secure additional business development opportunities.Hillhouse CapitalSeries B Preferred Stock FinancingUnited States
Cheplapharm Arzneimittel GmbH 210Atacand (candesartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist blocker (ARB) that is indicated for the treatment of hypertension and heart failure. Cheplapharm Arzneimittel GmbHDivestmentGermany
West Greenwich Facility200The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets.Amgen IncManufacturing InvestmentUnited States
Smithfield, Rhode Island Facility155The new facility will help the company scale its manufacturing process in order to produce large quantities of Red Cell Therapeutic product candidates and lentiviral vectors needed to encode biotherapeutic proteins inside or on the surface of each Red Cell Therapeutic. The facility will be customized to contain multiple manufacturing suites, which will enable Rubius to conduct its manufacturing operations in a cGMP compliant manner for clinical supply and, if approved, for the commercial supply Rubius TherapeuticsPurchase and Sale AgreementUnited States
LinkDoc Technology Ltd.151LinkDoc collects and standardizes healthcare data, covering more than 3,000 diseases, from hospitals and provides customized data for healthcare regulators, researchers, insurers and pharmaceutical companies. It has partnered with about 500 first-tier hospitals in more than 30 provinces and regions in China.China Investment Corporation (CIC)Series D FinancingChina
Ascentage Pharma150Ascentage Pharma has 16 active clinical trials in the U.S., Australia, and China, which the Company believes makes it one of the few companies with a robust portfolio of active clinical programs focused on both intrinsic and extrinsic apoptotic pathways. The Company's R&D products are aimed towards realizing the full potential of protein-protein inhibition in addressing promising targets in cancer.Oriza Seed Venture Capital Series C FinancingChina
Curon Biopharmaceutical150Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline, and is committed to bring next generation cancer immunotherapies to patients. Proceeds from the financing will be used to accelerate Curon’s pipeline assets into pre-clinical and clinical phases. 6 Dimensions CapitalSeries A FinancingChina
Medlinker147Medlinker is specially designed for doctors who can share their expertise, experiences, and opinions with other elites in the industry through the platform. It connects over 500,000 verified doctors with healthcare institutions, pharmaceutical companies, patients and insurance firms, according to its website.China Capital Zhongcai FundSeries D FinancingChina
Juniper Pharmaceuticals, Inc.140The acquisition combines Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe with of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.Catalent Pharma SolutionsAcquisitionUnited States
Compass Therapeutics132Compass is pioneering a new approach to identifying antibody drug candidates that engage all targets in the biologically complex human immune synapse, with an initial focus on T cells, NK cells and macrophages. The company’s lead product platform StitchMabs™ is a novel and proprietary high-throughput bispecific screening platform, enables the rapid identification of synergistic bispecific activity.F-Prime CapitalSeries A FinancingUnited States
Arcus Biosciences, Inc.130AB928 is an orally bioavailable, highly potent antagonist of the adenosine 2a and 2b receptors. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response.Taiho Pharmaceutical Co., Ltd.Option Exercise PaymentUnited States
Essen Technology129Essen Technology is a specialized enterprise of drug-eluting stents. Terumo has grown rapidly in China selling interventional products, such as guidewires and balloon catheters. Terumo has expanded its drug eluting stents' sales coverage to include Japan, Europe, Asia, and Latin America, for a total of over 40 countries.Terumo CorporationAcquisitionChina
BpiFrance116Sanofi has signed a memorandum of understanding with Bpifrance to launch InnoBio 2. By providing € 50 million to this fund, which will invest particularly in the digital sector, the company supports the development of innovative companies in the field of health, in France and Europe.Sanofi VenturesJoint InvestmentFrance
Janssen Sciences Ireland115SYLVANT® is the only FDA and EMA approved treatment for the rare disorder, idiopathic multicentric Castleman’s disease (iMCD). The acquisition of Sylvant leverages EUSA Pharma’s commercial and medical expertise in rapidly advancing therapies to address unmet patient needs and boosts EUSA Pharma’s presence in oncology and rare disease.Eusa PharmaAsset AcquisitionIreland
Beijing Allcure Medical Technology Co., Ltd.103China Health Industry Investment Fund Co.Ltd., a fund established by China Electronics Corporation Data (CEC Data), and Shanghai Jinpu Jiangfu Equity Management also participated in the round, according to Allcure Medical’s announcement.China Capital Investment Group (CCIG)Series B Preferred Stock FinancingChina
Crinetics Pharmaceuticals 102Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. J.P. Morgan SecuritiesIPOUnited States
Replimune Group, Inc.101Replimmune's Immulytic™ technology platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment.J.P. MorganIPOUnited Kingdom
Athenex, Inc.100The investment is part of the efforts to establish a joint venture with Xiangxue Life Sciences, a wholly-owned subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd. (Xiangxue Pharmaceutical), for the research, development and commercialization of T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, based on the novel approach on high-affinity TCR developed by Xiangxue Life Sciences;Perceptive AdvisorsInvestmentUnited States
I-Mab Biopharma100The two companies also agreed on a collaboration to co-develop additional bispecific antibodies (BsAb) as part of the partnership. The partneship focuses on ABL Bio to in-license the global rights excluding Greater China to I-Mab's bispecific antibodies (BsAb) of undisclosed target with licensing payments.ABL Bio CorporationPartnershipChina
Federal Communications Commission 100The $100 million telehealth initiative announced by the Federal Communications Commission (FCC) early July will largely focus on delivering virtual medical technologies directly to low-income patients in remote areas of the country, according to Commissioner Brendan Carr.Universal Service FundGrants & AwardsUnited States
Zavante Therapeutics98The Acquisition adds Zavante’s CONTEPO™, potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio.Nabriva Therapeutics plcAcquisitionUnited States
Sinovac Biotech Ltd.87Through the Private Placement, Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac and will fund the Improvement and Construction of Facilities for R&D Relating to Quality Control and Production of New Vaccines Projects.Vivo Capital, Advantech CapitalPrivate Placement China
Apotex International Inc. 86This acquisition will accelerate Aurobindo's European growth strategy, by strengthening its geographic reach and commercial infrastructure, particularly in the generics market of Eastern Europe; diversify Aurobindo's European product portfolio by adding over 200 generics and more than 80 over-the-counter (OTC) products that had total sales of EUR 133 million.Aurobindo Pharma Limited Business Unit AcquisitionCanada
TherapeuticsMD, Inc.85TherapeuticsMD intends to use the proceeds of the offerings to fund a portion of the costs for the commercial launch of its recently FDA approved product, IMVEXXY™ (estradiol vaginal inserts) for moderate-to-severe dyspareunia and to fund a portion of the costs for pre-commercialization and commercialization activities for TX-001HR, its bio-identical hormone therapy combination of 17-ßestradiol and progesterone in a single, oral softgel drug candidate.Goldman SachsIPOUnited States
TxCell S.A. 84The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg DevelopmentSangamo Therapeutics, Inc. AcquisitionFrance
SmartAnalyst, Create NYC82Create NYC offers the tactical execution of sales and marketing materials for its international pharmaceutical clients. SmartAnalyst provides strategic consulting services to pharmaceutical and biotech companies to support disease, asset, and portfolio level decisions. SmartAnalyst also provides Health Economics and Outcomes Research (HEOR) services, which uses evidence based data and analytics to demonstrate the value of products and to support market access and reimbursement with payors.UDG Healthcare AcquisitionUnited States
Global R&D Operations Hub77The Hub will support the clinical research and development of Sanofi's innovative drugs by focusing on the management of global multi-center clinical trials data and files. The Chengdu Hub will target diseases that affect millions of people across our therapeutic areas: diabetes and cardiovascular diseases, vaccines, oncology, immunology and inflammation, rare diseases, multiple sclerosis and neurology. SanofiManufacturing InvestmentChina
Daiichi Sankyo76Daiichi Sankyo has examined the business optimization of domestic long-listed products. The agreement entitles inventories of a total of 41 products, which comprise 35 of Daiichi Sankyo’s long-listed products and six of Daiichi Sankyo Espha’s long-listed products, to be be transferred to Alfresa Pharma from March 2019, for which Daiichi Sankyo and Daiichi Sankyo Espha are expected to receive payment of ¥8.42 billion.Alfresa Pharma CorporationSplit OffJapan
Spero Therapeutics, Inc.75Spero is a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections.Cowen and CompanySeries A Preferred Stock OfferingUnited States
Natera Inc75Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease.J.P. MorganIPOUnited States
Sutro Biopharma60To discover and develop immune-modulating therapies for cancer and autoimmune diseases.MerckCollaborationUnited States
Omniome, Inc.60The company will continue to optimize the novel Sequencing By Binding™ (SBB™) technology while accelerating prototype development of commercially-impactful sequencing platforms.Decheng Capital, Hillhouse Capital GroupSeries B FinancingUnited States
Nohla Therapeutics56Dilanubicel is a universal, off-the-shelf stem and progenitor cell therapy designed to provide short-term bone marrow function, while also providing long term immunologic benefits with the potential for improved survivalFidelity Management Series B FinancingUnited States
Dynacure55This financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs for other orphan disorders.Andera PartnersFinancingFrance
Spero Therapeutics, Inc.54The funding will support the further clinical development of Spero’s oral carbapenem product candidate, SPR994, for the treatment of complicated urinary tract infections (cUTIs) caused by antibiotic resistant Gram-negative bacteria. This is an exclusive inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994 and Initiate activity towards planned pivotal Phase 3 trial of SPR994 on track to initiate around year-end 2018.Biomedical Advanced Research and Development Authority (BARDA)Grants & AwardsUnited States
Immatics Biotechnologies GmbH54Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT® technology. Genmab will be responsible for development, manufacturing and commercialization worldwideGenmab A/SPartnershipGermany
Adlai Nortye Biopharma Co.53Adlai Nortye is advancing a robust pipeline of more than 10 diverse product candidates, focusing on novel treatments for cancer, with primary concentration on immuno-oncology. Adlai Nortye has two clinical stage immune-oncology product candidates. Reolysin®, an intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors is ready to enter Phase III study.YuanMing CapitalSeries B FinancingChina
Veracyte, Inc.51Veracyte may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies or other assets, although it has no present commitments or agreements to do so.Leerink PartnersIPOUnited States
Nabriva Therapeutics plc50Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections.Morgan StanleyIPOIreland
Liquidia Technologies, Inc.50Liquidia applied its engineering platform to the ingredient, treprostinil, to create trefoil-shaped, uniformly-sized particles. Liquidia thinks the tweaks may reduce the particle deposition in the upper airways that occurs when Tyvaso is delivered via nebulizers, resulting in more of the active ingredient penetrating deep into the lungs.Jefferies and CowenIPOUnited States
Atlantic Island Cannabis (FSD Atlantic Pharma)48Through its FV Pharma unit, the company holds a producer’s license from Health Canada and is headquartered in the former Kraft plant about an hour outside Toronto in Cobourg, Ontario.FSD PharmaAcquisitionCanada
Transgene48Transgene is transferring its 50% share of the current Transgene-Tasly joint venture (Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd.) to Tasly Biopharmaceuticals, making it the 100% owner of the joint venture entity and the greater China patent rights to T601.Tasly BiopharmaceuticalsStrategic AgreementsFrance
Cue Health Inc.45Cue Health Inc. (“Cue”) is an ISO 13485 certified company focused on developing and manufacturing consumer and professional medical diagnostic products that can be used in clinical or at-home settings. Cue’s mission is to create tools that empower physicians and consumers by increasing their access to actionable health data.Johnson & Johnson Development Corp.Series B FinancingUnited States
HotSpot Therapeutics45Regulatory hotspots offer a privileged subset of allosteric sites that remain unexplored for drug discovery and represent a major opportunity to create first-in-class medicines across multiple disease areas. This allows us to create medicines that work through exactly the same mechanisms, offering the same degree of precision and potency.Atlas VentureSeries A FinancingUnited States
World Health Organisation (WHO)41Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally.NovartisDrug DonationUnited States
Mitra Biotech (Mitra RxDx)40Mitra's CANscript™ platform delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development.Northpond VenturesFinancingUnited States
Neuraly36The company’s pipeline is centered around NLY01, a potent, brain-penetrant long-acting Glucagon-like peptide-1 receptor (GLP-1R) agonist that has demonstrated promise as a neuroprotective agent for neurologic disorders such as Alzheimer’s disease and Parkinson’s disease.Smilegate InvestmentFinancingUnited States
Mirren (Pty) Ltd33According to Cipla, the transaction will enhance Cipla’s OTC portfolio by adding Mirren’s well-established brands such as Bronco! cough syrup, Coryx, Tensopyn and Ultimag. The deal will also increase Cipla’s manufacturing footprint in Africa.Cipla Medpro South AfricaAcquisitionSouth Africa
Cue Health Inc.30The Cue Health Monitoring System centers around a connected diagnostic device, which enables a range of in-home and in-clinic diagnostics. It uses a custom designed reader to test clinical samples in a disposable test cartridge and then sends the results to a mobile application.Human Services’ Biomedical Advanced Research and Development Authority (BARDA)Grants & AwardsUnited States
Lyvgen Biopharma30Lyvgen’s leading cross-link antibody (xLinkAb) platform and co-stimulation agonist antibodies is readily utilizable for developing first-in-class and best-in-class therapeutics for major diseases, such as cancer. Lyvgen’s xLinkAb technology has shown to selectively activate specific receptors in the tumor microenvironment, while reducing immune-related adverse effects in the healthy tissue.6 Dimensions CapitalSeries B FinancingChina
Adaptimmune Therapeutics plc28GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognizing with high affinity the tumor-specific antigen, NY-ESO. GlaxoSmithKline plcAsset TransitionUnited Kingdom
AcelRx Pharmaceuticals 20AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain.Cantor Fitzgerald & Co.IPOUnited States
Cannara Biotech (FSD Pharma Inc.)18FSD is a significant Cannara shareholder and has applied for a second site license at the Cannara facility. FSD made an investment of $1 million dollars in this round of financing. First Republic Capital Corp. was the sole broker for the offering, the proceeds of which will support the first Phase build-out at Cannara’s Farnham, Quebec facility, as well as fund product development.First Republic CapitalEquity FinancingCanada
Click Therapeutics17Click will use this financing to continue advancing its proprietary platform and pipeline of prescription digital therapeutics to treat a wide range of diseases. Recent notes were converted to equity as part of the financing.Sanofi VenturesFinancingUnited States
EOS Imaging17EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services.Fosun Pharmaceutical AG (Shanghai Fosun Pharmaceutical Group)Equity InvestmentFrance
Seventh Wave Laboratories, LLC16By combining offerings, the two companies expect to capitalize on their collective skill sets, expertise, and assets to create a comprehensive portfolioBioanalytical Systems, Inc.Asset AcquisitionUnited States
Modus Therapeutics16Modus's lead candidate drug sevuparin is an innovative, proprietary polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. Currently being evaluated in a Phase II clinical study, sevuparin has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD.HealthCapFinancingSweden
Orig3n15The Series B financing will support Orig3n's international and domestic expansion as well as continued R&D development, empowering customers to access information about their genes to make educated, proactive choices about their lifestyles. Furthermore, the funding will also allow Orig3n to advance its breakthrough regenerative medicine treatments using the world's largest allogenic bank of cells that is HLA-matched to 90% of the U.S. population.Haitong InternationalSeries B FinancingUnited States
Octave Bioscience14This financing will allow the company to complete development of its proprietary, first-in-class platform and begin to evaluate the impact of the platform in its initial disease state, multiple sclerosis. Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis and other neurodegenerative diseases.BCBS Venture PartnersSeries A FinancingUnited States
MabVax Therapeutics11The asset acquisition is separate and distinct from other programs under development at MabVax, enabling MabVax to retain all rights to its lead HuMab-5B1antibody program which is in Phase 1 clinical trials as a therapeutic product and as a diagnostic product, as well as other antibody discovery programs from the Company's rich antibody discovery portfolio targeting other cancer antigens.Boehringer IngelheimAsset AcquisitionUnited States
Benitec Biopharma10License grants Axovant worldwide rights to AXO-AAV-OPMD, an investigational Silence-and-Replace gene therapy program which suppresses mutant protein production while restoring expression of functional protein. Axovant and Benitec plan to initiate placebo-controlled study of AXO-AAV-OPMD in patients with oculopharyngeal muscular dystrophy (OPMD) in 2019Axovant SciencesLicensing AgreementAustralia
Antoxerene (Ichor Therapeutics, Inc)10The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Antoxerene, Inc., a portfolio company of Ichor Therapeutics, is a small molecule drug discovery platform. Juvenescence Limited is an investment company focused on therapies to increase human longevity and complementary investments in related sectors.Juvenescence LtdJoint VentureUnited States
Pneuma Respiratory, Inc.8Pneuma Respiratory, Inc. ("Pneuma") has developed the PNEUMAHALER™ Breath Activated Digital Inhaler (BDI) to solve the problems of existing metered dose, dry- powder, and soft-mist inhalers to improve the efficacy of currently available airway medications. UndisclosedSeries A FinancingUnited States
Nextbiotix8It is Nextbiotix’s ambition to bring gut microbiota back into the therapeutic equation using a bacterium called Faecalibacterium prausnitzii. Nextbiotix is developing microbiome-based therapies using single microbial strains that interact with human cells in the gut. Acting more effectively on immunomodulatory pathways, they are intended to significantly improve the lives of patients suffering from inflammatory bowel diseases.Auriga PartnersSeries A FinancingFrance
Cingulate Therapeutics8The company has now raised over $16M as it positions itself for continued growth. Proceeds will be used to advance Cingulate's two (2) proprietary, first-line medications for the treatment of ADHD, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), through investigational new drug applications and Phase I/II clinical trials.Werth Family Investment AssociatesEquity InvestmentUnited States
Greifswald Mfg Site7The extension with state-of-the-art office space will be completed by the end of 2019. Thus, the pharmaceutical company has enough space for a total of 250 employees on approximately 8,000 square meters.Cheplapharm Arzneimittel GmbHManufacturing InvestmentGermany
Inversago Pharma7Inversago’s technology, based on the work by CB1 world expert George Kunos at the National Institute of Health (NIH/NIAAA), has demonstrated that in preclinical models, peripherally restricted CB1 blockade provides a clear therapeutic potential to treat conditions like obesity, NASH, liver fibrosis and diabetes, without causing the CNS or behavioural effects associated with the earlier generations of CB1 blockers.Genesys CapitalSeries A FinancingCanada
Presage Biosciences6Presage's CIVO platform has been developed for Phase 0 trials, also known as exploratory investigational new drug applications. The CIVO platform Phase 0 studies use minute amounts of experimental drugs to assess pharmacodynamics effects in patients. The use of the platform reduces toxicity concerns in traditional Phase I trials, the company said, as intratumoral microdosing uses approximately 100-fold lower doses of drug candidates.Takeda, CelgeneSeries D FinancingUnited States
Isotopen Technologien München AG (ITM)6ITG will provide Endocyte with 100% of thehighly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta® to support clinical and commercial supply of 177Lu-PSMA-617 required for the phase 3 VISION trial. Endocyte, Inc.Supply AgreementGermany
LexaGene Holdings Inc.6The Company intends to use the net proceeds of the Offering to advance the commercializing process of the Company's Microfluidic technology.Canaccord Genuity Corp.Private Placement Canada
Doctor Anywhere6The funding round will enable the start-up to expand the team, explore new business verticals, develop more healthcare solutions and thereby continue developing its products and services that will boost healthcare accessibility in Singapore,Kamet Capital PartnersSeries A FinancingSingapore
HealthSignz5The funds raised will be used to build additional features for Health Intelligence Engine (HIE) and to enhance services from HealthSignz platform to reach all healthcare providers.Nirvana Health GroupFinancingIndia
ABL Bio Corporation4Through the agreement, TRIGR gets global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer. These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb, 4-1BB/ undisclosed target BsAb); and a monoclonal antibody against undisclosed target.TRIGR TherapeuticsCollaborationSouth Korea
Fibrocell Science, Inc.4Fibrocell intends to use the net proceeds from this offering for the continued clinical and pre-clinical development of its product candidates, FCX-007 and FCX-013.H.C. Wainwright & Co.IPOUnited States
Cyrcadia Asia4The Pre-A funding will enable Cyrcadia to complete product development and launch into Hong Kong and other Asian markets in late 2018.iFlytekPre-Series AHong Kong
HealthPlix3HealthPlix will use the funds to strengthen its technology and expand its team and services in other geographical markets. IDG Ventures IndiaSeries A FinancingIndia
DNA Script3DNA Script is one of eight companies to receive an award for the "Concours d'Innovation 2018" of Bpifrance in the "Healthcare" division. DNA Script introduces a novel biochemical process for DNA and RNA synthesis based on the use of highly efficient enzymes. It will enable the production of long DNA constructs, which are key components of cell and gene therapies.BpifranceGrants & AwardsFrance
Bioasis Technologies, Inc2Bioasis will use the net proceeds from the private placement to support ongoing research and development, clinical development, manufacturing and other activities in respect of the Company’s clinical development pipelineUndisclosedPrivate Placement Canada
DILIsym Services, Inc.,2The goal of this project is to provide software that can be used in drug development efforts to predict a drug’s potential to cause drug-induced kidney injury, as well as assess and improve the understanding of mechanisms of drug-induced kidney injury.National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK)Grants & AwardsUnited States
MedTech and Pharma Growth Centre (MTPConnect)2MTPConnect - the Australian Government's Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre - in conjunction with the Western Australian Government and The University of Western Australia (UWA), is delighted to announce the establishment of the Western Australian Node (the WA Node) of MTPConnect in Perth, to support the state's burgeoning life sciences sector.Government of Western Australia, The University of Western AustralianCollaborationAustralia
Curious2018 – Future Insight Prize1The prize will be presented to researchers who will make outstanding contributions to enable innovations important for the future of humanity in the categories of health, nutrition and energy.Merck KGaAGrants & AwardsGermany
A-Alpha Bio0.23The National Science Foundation grant will be used to commercialize a synthetic biology platform for cancer drug development. National Science Foundation Phase I Small Business Innovation ResearchGrants & AwardsUnited States
Cannevert Therapeutics Ltd. (Veritas Pharma)0.16Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.Sativa Investments PLCIntellectual Property Sharing AgreementCanada
Sastomed GmbHUndisclosedThe deal adds new, award-winning products to Molnlycke's offer – enabling it to further help healthcare professionals and patients by accelerating the wound healing process and treating chronic wounds. SastoMed GmbH joins the Molnlycke family, bringing two innovative and complementary products to Molnlycke's wound care portfolio: Granulox and Granudacyn.MolnlyckeAcquisitionGermany
Adamis Pharmaceuticals Corporation UndisclosedSandoz will obtain the United States commercial rights to Symjepi in exchange for an upfront fee and potential performance-based milestones payments. Sandoz will have commercial rights to the FDA-approved Symjepi (epinephrine) Injection 0.3mg product, as well as the Symjepi (epinephrine) Injection 0.15mg product if approved by the FDA.Sandoz Inc.Distribution AgreementUnited States
PV Nano Cell Ltd.UndisclosedPV Nano Cell is the developer of the state-of-the-art Sicrys™ conductive inks based on single crystal nano particles of silver and copper. The performance material division of Merck is evaluating Sicrys single crystal metal particles with different, unique and patented technologies and applications.MerckSupply Agreement Israel
AXM Pharma, Inc.UndisclosedThe shares of the Common stock representing 70% of the outstanding Capital Stock of AXM Pharma to be issued to Mr. Emmanuel Neossi for the acquisition of ASIC in the merger will be restricted, therefore there will be no change in the public float of the Company and there will be no reverse stock split either. The transaction is accretive to the current shareholders of AXM Pharma, Inc. as it also remains beneficial to the target on the other hand.Mr. Emmanuel Neossi (AS Industries Cameroon)Reverse Merger AgreementUnited States
Array BiopharmaUndisclosedBRAFTOVI (encorafenib) and MEKTOVI (binimetinib) were approved by The U.S. Food and Drug Administration (FDA) on June 27, 2018 based on clinical data from the Phase 3 COLUMBUS study. They are prescribed to treat patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.Onco360Distribution Network AgreementUnited States
Acentrus SpecialtyUndisclosedLicenseLogix provides comprehensive business licensing solutions, including tracking of pharmacy licensure changes, research of license requirements, filing of new applications, and full outsourcing of all license renewals with access to the web-based Client License Information Center—CLiC.LicenseLogixPartnershipUnited States
Center for Pharmacy Practice Accreditation (CPPA)UndisclosedCPPA is a partnership established by ASHP (American Society of Health-System Pharmacists), the American Pharmacist Association (APhA), and the National Association of Boards of Pharmacy (NABP) to oversee accreditation of pharmacy practice sites. CPPA develops standards and provides accreditation programs for specialty, community, and telehealth pharmacy practices.Acentrus SpecialtyPartnershipUnited States
Institute of Molecular Biotechnology GmbH (Medical University of Vienna)UndisclosedThe agreement grants APEIRON an exclusive worldwide license to a novel immunotherpay product targeting casitas B cell lymphoma-b. The immunotherapeutic APN401 works by inhibiting Cbl-b which not only distinctly activates immune cells but can deactivate other relevant checkpoints, including CTLA-4 and PD-L1/PD-1. Hence, Apeiron regards it as the “master checkpoint” in cancer immunotherapy.APEIRON Biologics AGLicensing Agreement Austria
Fullerton Healthcare Corporation Ltd.UndisclosedThe parties signed a Memorandum of Understanding (MoU) that will see Microsoft as a partner in driving the transformation of Fullerton Health's existing technology infrastructure, as well as introducing intelligent services such as Artificial Intelligence (AI) in their existing processes. The partnership also aims to drive innovation within the healthcare sector through co-creation of scalable solutions.Microsoft Asia PacificMemorandum of UnderstandingSingapore
HIMSS Asia PacificUndisclosedHIMSS AsiaPac18 will be convened under the theme Healthcare Anytime, Anywhere. The key topics that the event will be addressing are Connect – Telehealth, Interoperability, Health Information Exchange, Integrated Care; Consumer-Partnership – Engagement, Connected Health, Team-Based Care, Consumer-Centred Care; Sustainability – Innovative Business Models, Value-Based Care, Margin and Outcome Management, Collaboration; Data – Genomics, Cybersecurity, Artificial Intelligence, Internet of Things, BloeHealth QueenslandTreaty AgreementAustralia
Mercy (IBM Watson Health)UndisclosedTogether, the companies will utilize an established data platform launched by Mercy (IBM Watson Health) that uses real-world clinical data to evaluate medical device performance. Johnson & Johnson Medical Devices Companies (JJMDC)CollaborationUnited States
A. Menarini Asia-Pacific Holdings Pte LtdUndisclosedThis multi-year licensing agreement enables Menarini Asia-Pacific to distribute and commercialize several of Orion's Easyhaler® products in China, Hong Kong, Philippines, Malaysia, Indonesia, Thailand, Singapore, Vietnam, Taiwan, and South Korea. Orion's proprietary dry-powder inhaler Easyhaler® is used for administering medication for the treatment of asthma and COPD. Orion CorporationLicensing Agreement Singapore is designed with convenience and easy navigation in mind, ensuring that patients and physicians can easily access the information they need, anytime and everywhere. This new online platform demonstrates Merck’s commitment to continuing to support people trying to conceive, whilst also offering HCPs a scientific platform with the latest advances in reproductive medicine.Merck KGaALaunchGermany
A*STAR's Institute of Molecular and Cell Biology (IMCB), Indivumed GmbHUndisclosedThis contributes to Indivumed’s global cancer database solution “IndivuType”, funded by the European Investment Bank and private investors. IndivuType combines comprehensive cell biological information such as genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data with extensive clinical information from thousands of patients.European Investment BankResearch AgreementSingapore
AMW GmbH - Arzneimittelwerk WarngauUndisclosedAMW GmbH is a specialty pharmaceuticals company headquartered in Warngau near Munich, Germany. It develops, produces and sells drug delivery systems with a focus on biodegradable implants and transdermal treatment systems. The company was founded in 2008 and develops solutions for use in oncology, neurology, dermatology and pain management applications.Yunfeng Capital, Hybio PharmaceuticalAcquisitionGermany
Mitsui Chemicals Agro, Inc.UndisclosedBayer to expand its strong parasiticide portfolio for companion animals with new compounds derived from MCAG’s chemical library / License agreement is the result of the long-term collaboration between Bayer and MCAGBayer Animal Health GmbHLicensing Agreement Japan
Kent ImagingUndisclosedThis is a great partnership between one of the leaders in building wound care teams and an innovative tissue assessment technology that is easy to use, convenient, and cost effective. SerenaGroup® will adopt Kent Imaging's technology as the standard of care for assessing wound oxygenation thus wound health. Kent will be integrated into each of the SerenaGroup® managed facilities, included in Hyperbaric training courses curriculum, as well as included in future clinical and preclinical researSerenaGroupPartnershipCanada
Neovii pharmaceuticals AGUndisclosedThe agreement gives Mundipharma the rights to develop and distribute Neovii's polyclonal antibody immunosuppressant, Grafalon®, in China and Japan from end October.MundipharmaIn-licensing Agreement Switzerland
Technische Universität Dresden (TU Dresden)UndisclosedAt the centre of the R&D Collaboration is the team of denovoMATRIX employed by TU Dresden which will conduct examinations into the tentative synergy between Cellect's ApoGraft™ and the denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine. To that end, a denovoMATRIX scientist will conduct a line of experiments in Cellect's R&D facility in Israel.Cellect Biotechnology Ltd.CollaborationGermany
Cleara BiotechUndisclosedCleara has partnered with Dr. Peter de Keizer from the University Medical Center in Utrecht, Dr. Marco Demaria from the University Medical Center in Groningen, and Dr. Tobias Madl from the Medical University of Graz to engage in its discovery operations. Cleara’s initial funding was led by founding investor Apollo Ventures.Apollo Ventures, University Medical Center Utrecht, University Medical Center GroningenCollaborationThe Netherlands
Memorial Sloan Kettering Cancer CenterUndisclosedGrant intended to evaluate the utility of MVT-2163 to improve pre-operative staging of patients with pancreatic cancer. MabVax Therapeutics discovered the HuMab-5B1 antibody from patients treated at MSK with a vaccine developed by Dr. Philip Livingston. In collaboration with MSK, the Company established the preclinical proof of concept for using the HuMab-5B1 immunoPET imaging agent for improving the visualization of pancreatic cancer.National Institutes of Health Grants & AwardsUnited States
Isotopen Technologien München AG (ITM)UndisclosedThis partnership aims to meet the medical community’s growing demand for radionuclides for use in Targeted Radionuclide Therapies. N.c.a. Lutetium-177 will be produced at Bruce Power’s CANDU reactors while development, processing, and global distribution of n.c.a. Lutetium-177 will be managed by ITM.Bruce PowerMemorandum of UnderstandingGermany
Glenmark Pharmaceuticals Ltd.UndisclosedGlenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialization of the product in Australia and New Zealand. Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)) is a novel, investigational, fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. Seqirus Pty. Ltd.Licensing Agreement India
Predicine, Inc.UndisclosedThe aim of the partnership is to increase the speed and efficiency of biomarker-driven global clinical trials for Kintor's novel oncology drugs and the development of companion diagnostics for FDA and CFDA approvals. Kintor will leverage Predicine's ctRNA + ctDNA liquid biopsy technology, GeneRADAR, and expertise in genomics and molecular information to advance the development of its oncology pipeline.Suzhou Kintor Pharmaceuticals PartnershipUnited States
Cellect Biotechnology Ltd.UndisclosedThis Agreement secures exclusive clinical production capacity of the main active ingredient in Cellect's ApoGraft™. The FasL protein is a key active ingredient in Cellect's product line and technology for cell separation and functional selection of stem cells. As Cellect advances in its product development, it becomes essential to secure a consistent and reliable supply of pharma-grade FasL.Swiss Biotech CenterSupply Agreement Israel
Pluristem Therapeutics Inc. UndisclosedThe collaboration combines Thermo Fisher’s experience in cell therapy development and bioproduction scaleup with Pluristem’s expertise in cell therapy manufacturing, clinical development and quality control.Thermo Fisher ScientificCollaborationIsrael
University of British Columbia (UBC)UndisclosedTxCell's TX200 is a HLA-A2 CAR-Treg program which originated in the laboratories of Dr. Megan Levings, UBC in Vancouver, Canada, who established the first preclinical proof of concept with human HLA-A2-specific CAR-Treg cells in a preclinical model of Graft vs. Host Disease. TxCell SAIn-licensing AgreementCanada
BioVaxys LLCUndisclosedBioVaxys’ immunotherapeutic approach is based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. This exclusive worldwide license agreement is for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor types.Thomas Jefferson UniversityLicensing AgreementUnited States
TVA Medical, Inc.UndisclosedThe addition of TVA Medical enables BD to offer the everlinQ™ endoAVF System, a new endovascular arteriovenous (AV) fistula creation technology that adds to the company's ESRD portfolio of dialysis catheters, drug coated balloons, standard angioplasty balloons and endovascular stent graft products.Becton DickinsonAcquisitionUnited States
Optivia BiotechnologyUndisclosedThe announced acquisition of Optivia strengthens BioIVT's transporter sciences capabilities and enables it to partner with customers on new drug applications. BioIVT's portfolio now includes all of Optivia's products, including its Opti-Expression™ technology, Opti-Target™, Opti-DDI™, and Opti-ADME™ Transporter Services Panels, and its TransFlex™ Single Transporter and Multi-Transporter Assay Plates.BioIVTAcquisitionUnited States
ONO Pharmaceutical Co., Ltd.UndisclosedCluePoints and ONO will now continue to work in close partnership over the next four years to build on the success of the pilot program. Experts from CluePoints in Japan will deliver on-site training and provide ongoing support to the ONO team to ensure the adoption of the RBM approach delivers the best possible results.CluePointsPartnershipJapan
Adlai Nortye Biopharma Co.UndisclosedBuparlisib (BKM120) is an oral pan-PI3K inhibitor that targets all class 1 PI3K isoforms and is active in both hematologic malignancies and solid tumors. This License Agreement grants Adlai Nortye the exclusive rights to develop and commercialize buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans.Novartis Pharma AGLicensing Agreement China
FSD PharmaUndisclosedFSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility. Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers. FSD Pharma and Canntab see trCanntab TherapeuticsProfit Sharing AgreementCanada
Berkeley Lights, Inc. (BLI)UndisclosedCatalent Biologics will adopt Beacon®optofluidic platform to accelerate its cell line development workflow. he Beacon platform is capable of screening thousands of clones in parallel. The four integrated workflows of the Beacon platform – import, culture, assay, and export, will be applied to Catalent Biologics’ GPEx®cell line development platform, as well as Catalent’s ongoing research and development activities.Catalent Biologics (Catalent Pharma Solutions)PartnershipUnited States
Genevant SciencesUndisclosedBioNTech and Genevant will develop five products for rare diseases with high unmet medical need under the 50/50 co-development and co-commercialization collaboration, combining Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics.BioNTech AG CollaborationSwitzerland
4D Molecular TherapeuticsUndisclosedThe collaboration will leverage 4DMT’s expertise in vector discovery and engineering, optimization and process development. MedImmune will conduct product development beginning from early clinical stages, drawing on the company’s extensive expertise in respiratory science.MedImmune (AstraZeneca)CollaborationUnited States
ReCor Medical, Sofinnova PartnersUndisclosedReCor Medical is an innovative medical device company that developed the Paradise® System, a proprietary ultrasound ablation system for renal denervation - a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions.Otsuka HoldingsAcquisitionUnited States
Ajinomoto Co., Inc.UndisclosedThe Collaboration is primarily for the development of FB-2710 for Radiation-Induced Oral Mucositis. FB-2710 is designed for optimal bioavailability and cellular uptake of glutamine, a critical nutrient and energy source for rapidly-dividing cells that regenerate the lining of the gastrointestinal tract. Filament BioSolutionsCollaborationJapan
Pionyr ImmunotherapeuticsUndisclosedProBioGen will perform process development and GMP manufacturing on a second antibody from the Pionyr pipeline using their high performance CHO.RiGHT® expression platform. Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline, enabling a rapid advance to clinical trials.ProBioGen AGLicensing AgreementUnited States
ETHOS Health CommunicationsUndisclosedETHOS has an authority in understanding and translating the science of medicine into high-level strategy and tactical execution. With a track record of long-tenured relationships with major biopharmaceutical companies and leading biotechnology firms, ETHOS has established a leadership position in the delivery of strategic scientific and medical communications and training solutions.Precision Medicine Group, Inc.AcquisitionUnited States
SRI Biosciences (SRI International)UndisclosedSRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) can deliver more than a dozen different types of payloads - from functional enzymes, antibodies and DNA, to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered undruggable. Ionis PharmaceuticalsCollaborationUnited States
Yale School of Medicine, Brigham and Women's HospitalUndisclosedNuMedii will work with the Yale School of Medicine with the goal of utilizing single-cell sequencing to identify novel precision therapies and biomarkers in idiopathic pulmonary fibrosis (IPF) - an orphan chronic fatal interstitial lung disease.NuMedii, Inc.CollaborationUnited States
908 DevicesUndisclosedHJB has recently launched a world-class pharmaceutical development facility in Hangzhou, Zhejiang where only leading-edge technologies — including the 908 Devices ZipChip® platform — will be integrated into their on-site processes. 908 Devices also announced the availability of their ZipChip platform in China.Hangzhou Just Biotherapeutics (HJB)PartnershipUnited States
Highmark Inc.UndisclosedThe contract focuses on an analysis of the total cost of care for adults with type 2 diabetes and established cardiovascular disease who have been prescribed Jardiance, compared with people who have not been prescribed Jardiance.Boehringer IngelheimContract AgreementUnited States
Innovative Medicines; Established Medicines; Consumer Healthcare UndisclosedPfizer Inc. announced that it will organize itself into three businesses: a science-based Innovative Medicines business that would include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These changes will be effective at the beginning of the company’s 2019 fiscal year. Pfizer Inc. Business Re-organisationUnited States
Boehringer IngelheimUndisclosedThe collaboration builds upon the efforts to market two new oral anti-diabetics drugs, Gibtulio Met (Empagliflozin+ Metformin) and Ajaduo (Empagliflozin +Linagliptin), which were recently approved by the Drugs Controller General of India. The two products will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names.Lupin LimitedCo-marketing AgreementIndia
EUSA PharmaUndisclosedThe transaction includes a portfolio of products, which are marketed across a range of countries, and EUSA's field-based critical care sales teams in the UK, France, Netherlands, Belgium and Poland. The portfolio is based around COLLATAMP®, which is marketed for the prevention of infection during surgery across Europe and a wide range of countries outside the United States, including South Korea and South Africa.SERB PharmaceuticalsBusiness Unit AcquisitionUnited Kingdom
ResMedUndisclosedCombining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, the U.S.-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea, and develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat and manage individuals with sleep apnea and other breathing related sleep disorders.Verily Life SciencesJoint VentureUnited States
Blink Health PartnersUndisclosedThrough Blue Eagle, Blink Health is able to offer its pharmacy partners complete transparency into how much they will be paid for every prescriptionBlue Eagle HealthPartnershipUnited States
BMG Pharma S.p.A.UndisclosedThe new company will give BMG the opportunity to rapidly complete the development of a number of new patent protected products with topical and subcutaneous applications, which it will be able to offer to its network of global marketing partners for the benefit of patients globally.Sigea S.r.l., BMG Pharma S.r.l., LaunchItaly
BioAgilytixUndisclosedThrough this partnership, Bioasis will have access to BioAgilytix’s extensive bioanalytical expertise, particularly in ligand binding assays, anti-drug antibody detection, stability assessments across complex matrices and highest quality GLP validation of complex assays. Bioasis Technologies, IncCollaborationGermany
Scientist.comUndisclosedThe partnership between and HealthEconomics.Com will provide an effective method to connect RWE researchers with service providers to simplify the research sourcing process, save money and enhance market access.HealthEconomics.ComPartnershipUnited States
CAS, American Chemical Society (ACS)UndisclosedThis agreement provides enterprise-wide access to the newest solution in the SciFinder® family, SciFindern. With SciFindern, scientists can quickly find the most relevant, actionable answers for their scientific inquiries to accelerate their research outcomes.Sumitomo Dainippon PharmaAccess AgreementUnited States
Mission: CureUndisclosedIn Stage One of the PerlQuest, Perlara will engineer ?F508 and 26 other cystic fibrosis transmembrane conductance regulator (CFTR) disease-causing variants in yeast YOR1 models of CFTR deficiency and then complete drug repurposing and drug discovery screens with the ?F508 model and another mutant, e.g., class III or class IV. The goal is to discover compounds for rapid testing in patient-matched organoid models.PerlaraPartnershipUnited States
COFCO CorporationUndisclosedThis strategic cooperation will be started with a two-week blood sugar monitoring project. Both the companies, COFCO Corp. and iCarbonX, are dedicated to build an individualized accurate blood sugar management model through long-term monitoring, observation, analysis and evaluation on abnormal blood glucose patients, so as to give personalized intervention and treatment plans for those specific groups, and effectively achieve their goal of health management.iCarbonX Cooperation AgreementChina
Xian Janssen Pharmaceuticals Ltd.UndisclosedThrough this agreement, the two companies will work closely together on future development, distribution, promotion, access, marketing and sales of INVOKANA® (canagliflozin) in the country and Merck will hold the exclusive rights for INVOKANA® (canagliflozin)'s promotion in China.Merck KGaALicensing AgreementChina
OrigiMedUndisclosedOrigiMed agrees to develop and promote its advanced molecular clinical tumor applications to the public based on the Next Generation Sequencing (NGS) technology of Illumina. IlluminaCollaborationChina
Sensile MedicalUndisclosedThe combination of the two companies will enable Gerresheimer to enhance its Drug Delivery offering for its Pharmaceutical and Biotech partners, especially with new digital and electronic capabilities.Gerresheimer AGAcquisitionSwitzerland
Miltenyi BiotecUndisclosedThe agreement provides combined use of MACSQuant® Tyto® Cell Sorter and cellenONE® X1 single-cell deposition unit allows for time- and cost-efficient production of high-expressing and fast-expanding monoclonal cell lines.Cellenion (Scienion AG)Co-marketing AgreementGermany
Glooko, Inc.UndisclosedInsulet’s partnership with Glooko is further proof of its commitment to putting customers first, as it ensures Insulet can continue to be closer to the diabetes community and provide personalised support for Podders™ across Europe.Insulet CorporationPartnershipUnited States
Chiba Plant FacilityUndisclosedMajor expansion of facilities at its Chiba Plant that will result in an approximately tenfold increase in the company's GMP(*1)-compliant synthetic pharmaceutical intermediate and active ingredient (*2) production capacity. TAGC GroupManufacturing InvestmentJapan
Arcus Biosciences, Inc.UndisclosedTaiho Pharmaceutical has obtained the exclusive right to develop and commercialize Arcus’s adenosine receptor antagonists (AB928) in Japan and certain other territories in Asia. AB928 is an orally bioavailable small molecule compound which inhibits the adenosine 2a and 2b receptors. The activation of these receptors by adenosine on tumor infiltrating immune cells is thought to be one of the key mechanisms of immuno-suppression in the tumor microenvironment.Taiho Pharmaceutical Co., Ltd.Commercialization AgreementUnited States
Alliance Global FZUndisclosedThis is a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept's Target Selector™ liquid biopsy tests in the United Arab Emirates and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region.Biocept, Inc.Distribution AgreementUnited Arab Emirates
BiosensiaUndisclosedThis acquisition demonstrates Kypha's commitment to meet the need for universally accessible, reliable and timely immune status results in virtually any setting from acute hospital care, to centralized laboratories, physician offices and home use. KyphaAcquisitionIreland
Storz & Bickel GmbHUndisclosedThe Co-development agreement is focused on combining Tetra Bio's PPP001 prescription drug (a future proprietary cannabinoid formulation) with the Mighty Medic - a portable herbal vaporizer for cannabis use approved by Health Canada as a Class 11 medical device and as such, is eligible for reimbursement. The agreement allows Tetra to effectively bring PPP001 to patients suffering from fibromyalgia and other chronic pain conditions, significantly expanding the market potential for PPP001.Tetra Bio-Pharma IncCo-development AgreementGermany
Calibra Medical, Inc. (LifeScan, Inc.)Undisclosed The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via™. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime. CeQur CorporationAsset AcquisitionUnited States
Sinovant SciencesUndisclosedRenexxion has granted Sinovant an exclusive license for the development and commercialization of naronapride in the People's Republic of China, Hong Kong, Macau, and Taiwan. Sinovant intends to initially develop naronapride in irritable bowel syndrome with constipation (IBS-C).RenexxionPartnershipChina
Sinovant SciencesUndisclosedBacked by Roivant Sciences and CITICPE, Sinovant began operations in 2017 and is led by co-founders Dr. Canwen Jiang and Dr. Xinan Chen. Sinovant has built a pipeline of 11 investigational biopharmaceutical products. The current pipeline consists of Derazantinib, a fibroblast growth factor receptor (FGFR) inhibitor for intrahepatic cholangiocarcinoma (iCCA), Lefamulin, an antibiotic targeted against community-acquired bacterial pneumonia (CABP).Roivant Sciences, CITICPELaunchChina
MylanUndisclosedAbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property, excluding Europe.AbbViePatent License AgreementsUnited States
Eureka Therapeutics Inc.UndisclosedThe licensed TCRm antibodies were developed from Eureka’s proprietary E-ALPHA® antibody discovery platform, which comprises a highly diverse human-derived antibody phage library containing over 100 billion clones with unique antibody sequences and a robust workflow with specificity screens designed to develop highly specific antibodies against target antigens. Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against aBoehringer IngelheimOption Exercise PaymentUnited States
Capricor TherapeuticsUndisclosedCAP-2003 is derived from Capricor’s proprietary cardiosphere-derived cells (CDCs), which comprise adult cardiac progenitor cells from donor heart tissue. CAP-2003 has shown promising results in various pre-clinical experiments using established animal models of diseases by exerting anti-inflammatory, anti-fibrotic, pro-angiogenic, and anti-apoptotic effects.U.S. Army Institute of Surgical Research (USAISR)CollaborationUnited States
Puma BiotechnologyUndisclosedStrata will exclusively refer HER2-mutated advanced cancer patients identified through the Strata Trial for consideration of enrollment to Puma’s SUMMIT Trial for neratinib. The Strata Trial is a screening protocol providing comprehensive tumor molecular profiling to advanced cancer patients at no cost and proactive enrollment support for a portfolio of pharma-sponsored precision therapy trials.Strata Oncology, IncCollaborationUnited States
Axis Therapeutics Ltd. (Athenex, Inc.)UndisclosedAxis Therapeutics, a newly established joint venture to be owned as 55% by Athenex and 45% by Xiangxue Life Sciences (a wholly-owned subsidiary of Xiangxue Pharmaceutical Co., Ltd.), will be primarily focused on the research, development and commercialization of T-cell receptor-engineered T cells (TCR-T), a form of cancer immunotherapy.Hong Kong Polytechnic UniversityMemorandum of Understanding (MOU)United States
TheramexUndisclosedIntrarosa is a unique non-estrogen prescription therapy approved for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women experiencing moderate to severe symptoms. The countries within the license agreement are: Australia, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, United Kingdom, the RussiEndoceutics IncLicensing AgreementUnited Kingdom
Gadeta B.V.UndisclosedGadeta has developed a proprietary technology to engineer alpha beta T cells with gamma delta TCRs, called TEGs, for the potential treatment of various hematological cancers and solid tumors. This platform has the potential to combine the advantages of conventional T cells, which express alpha and beta TCR chains, with TCRs derived from gamma delta T cells that recognize novel targets in cancer cells, according to preclinical models evaluating the lead TEG candidates.Kite Pharma (Gilead Sciences)CollaborationThe Netherlands
Asian Eye InstituteUndisclosedNovotech works in partnership with leading medical institutions across Asia to accelerate quality clinical research. The Asian Eye Institute, Inc (AEI) partnership is designed to give Novotech clients faster start-up times and access to the AEI patient database, and leading principal investigators.Novotech (Australia) Pty LimitedPartnershipPhilippines
CCM Pharma SolutionsUndisclosedNesvik Pharmaceuticals and CCM Pharma Solutions have agreed to work together to reformulate four new drug compounds (to be known as BSEM-120, BSEM-125, BSEM-130, and BSEM-135) via the 505(b)(2) pathway for U.S. FDA approval. These reformulations allow increased availability and delivery of widely known and used drugs in patients who are unable to take tablets or capsules.Nesvik Pharmaceuticals (BioStem Technologies)Asset AcquisitionMalaysia
Antengene CorporationUndisclosedThrough the R&D Collaboration, WuXi STA will provide Antengene an integrated solution in process R&D and manufacturing, using the MAH scheme to accelerate new drug development. Antengene and WuXi STA will also explore expanding the collaboration to commercial stage assets as Antengene prepares for the commercialization of its late-stage pipeline agents.STA Pharmaceutical Co., Ltd (WuXi AppTec)Development and Manufacturing AgreementChina
Shyft AnalyticsUndisclosedNovartis will use the following SHYFT solutions: STRATA Data Platform to aggregate and manage a growing number of third party and proprietary commercial data sources, LUMEN Insights Platform to deliver intuitively-designed analytics to drive the “next-best-actions” for commercial teams.Novartis Pharma AGPartnershipUnited States
Shyft AnalyticsUndisclosedShyft has evolved a variety of modules for its Intelligent Platform: Strata, for data analytics; Lumen, for data visualization (Tetraphase will be using these two products); Quantum, for performing analytics retrospectively, and Nova, for patient care coordination. Tetraphase PharmaceuticalsPlatform PartnershipUnited States
Tsinghua University Innovation Center for Immune Therapy (ICIT)UndisclosedThe Innovation Center for Immune Therapy of Tsinghua University will conduct research on projects and Bristol-Myers Squibb will have an option to exclusively license therapeutic agents discovered by Tsinghua University. BMS collaboration with Tsinghua University focuses on the discovery of therapeutic agents against novel targets for autoimmune diseases and cancers.Bristol-Myers SquibbCollaborationChina
Advanced TherapeuticsUndisclosedSince partnering with WayPoint Capital Partners, DME Express has continued its rapid organic and acquisition-based growth strategy, completing four add-on transactions and adding over 4,000 new patient census across several markets. Advanced Therapeutics' strong reputation and established relationships in the area, combined with its experienced staff, provide a solid platform for DME Express to further expand in the Mid-Atlantic and other parts of the country.DME ExpressAcquisitionUnited States
InnoCore PharmaceuticalsUndisclosedMerck and InnoCore Pharmaceuticals have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys® biodegradable polymer platform. The drug delivery platform can be used to develop sustained release solutions for biologicals in injectable formulations.Merck KGaACooperation AgreementThe Netherlands
MannKind CorporationUndisclosedThe agreement covers markets outside of the US where the product is yet to be registered. Under the terms of the deal, Tanner Pharma Group’s wholly-owned subsidiary TannerGAP will manage the distribution.Tanner Pharma Group (TannerGAP, Inc.)Distribution AgreementUnited States
Steward Health Care InternationalUndisclosedThe Letter of Intent outlines the willingness of both parties to co-operate in good faith with openness and transparency – all within the governing laws of Croatia, and the European Union informing a detailed assessment of the country's health care needs. As an integrated health care system, Steward's model addresses the wider health care needs of the populations and all ways to keep people healthy. Croatian Ministry of HealthLetter of Intent
Beckman CoulterUndisclosedThe iQ Workcell pairs two of the world's most highly regarded automated urine analyzers: the Beckman Coulter Iris iQ200 Digital Flow Morphology system and the ARKRAY AUTION MAX AX-4030 fully automated urine analyzer. This total urinalysis offering will be available in the U.S. exclusively through Beckman Coulter. U.S. ARKRAY, Inc.Product LaunchUnited States
Glycotope GmbHUndisclosedThe Global licensing agreement entitles Daiichi Sankyo to develop an antibody drug conjugate (ADC) by combining Daiichi’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX®), building on a previous 2017 option agreement.Daiichi Sankyo Company, Ltd.Licensing AgreementGermany
HiFiBiO TherapeuticsUndisclosedAccording to the agreement, scientists from both companies will work together to discover antibodies against Takeda’s targets using HiFiBiO Therapeutics’ single-cell screening capabilities. Takeda will be responsible for the preclinical and clinical development of the discovered antibodies.Takeda Pharmaceutical CompanyResearch AgreementChina
Dana-Farber Cancer InstituteUndisclosedDana-Farber researchers continue to be granted permission to conduct independent pre-clinical and clinical studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly.Eli Lilly and Company Oncology Collaboration Extension United States
Zarbee's, Inc.UndisclosedThe acquisition will include the full line of Zarbee's Naturals™ products for children and adults. Zarbee's Naturals™ has grown into a broad-based health and wellness brand and has disrupted the cough, sleep, immune support and vitamin categories with its portfolio of family-friendly products. Johnson & Johnson Consumer Inc.AcquisitionUnited States
Laekna Inc.UndisclosedThe candidates are oral pan-Akt kinase inhibitors. Over ten clinical Phase I/II studies for afuresertib (ASB183) and uprosertib (UPB795) have been conducted in several cancer indications including ovarian and gastric cancer, multiple myeloma, melanoma, and other indications. Novartis Pharma AGCommercialization AgreementChina
Eisai Co., Ltd.UndisclosedThe agreement grants exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name US - BELVIQ®, BELVIQ XR, “lorcaserin”) in China.CY BiotechCollaborationJapan
Centrillion Genomics TechnologiesUndisclosedThe strategic cooperation agreement includes a multi-million US dollar investment by WeDoctor and establishes with Centrillion (Hangzhou) Co., Ltd. a joint venture to provide the most advanced DNA chips and genomic analysis services.WeDoctor Holdings LimitedCooperation AgreementTaiwan
Centrillion Genomics TechnologiesUndisclosedAs the largest chipset provider for big data, AI, and the Internet of Things (IoT), Arm is bringing compute power to genomics and healthcare management to accelerate growth opportunities and technology innovation. Arm IoT Fund, sponsored by Arm Holdings is the world’s leading semiconductor intellectual property (IP) supplier for digital electronic products. Arm IoT FundFinancingTaiwan